Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020829 | 0.87 | HRH4 (0.34) | HRH4HSD17B10 | |
| SCHEMBL1350091 | 0.85 | LMNA (0.30) | — | |
| SCHEMBL1045304 | 0.85 | DRD2 (0.38) | HSD17B10KDM4E | |
| SCHEMBL173244 | 0.83 | HMGCR (0.46) | HMGCRHRH4HSD17B10KDM4E | |
| SCHEMBL29438115 | 0.79 | HRH4 (0.49) | HRH4HSD17B10KDM4E | |
| SCHEMBL2721824 | 0.79 | HRH4 (0.49) | HRH4HSD17B10KDM4E | |
| SCHEMBL29770713 | 0.77 | LMNA (0.42) | — | |
| SCHEMBL2625503 | 0.77 | LMNA (0.42) | — | |
| SCHEMBL2625506 | 0.77 | ALDH1A1 (0.38) | HRH4HSD17B10KDM4E | |
| SCHEMBL12133467 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-2906221-B1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RES INST (US) | 2019-05-15 | — | — | EP | disclosed |
| US-9969743-B2 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-07-06 | — | — | US | disclosed |
| US-9598387-B2 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2017-03-09 | — | — | US | disclosed |
| EP-3107910-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015124868-A1 | NEW PHENYLAZETIDINE, CARBOXYLATE OR CARBOXAMIDE COMPOUNDS | INVENTIVA (FR) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2906221-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | Southern Research Institute (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014059265-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2003002543-A1 | PYRIMIDINOXYALKYLPIPERAZINES AND THEIR THERAPEUTIC USE | ABBOTT LABORATORIES (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | HMGCR 3982/4885HRH4 1012/4885HSD17B10 4037/4885 |
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | HTR2C, HTR4, HTR2A | HMGCR 3219/4885HRH4 29/4885HSD17B10 1349/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | HMGCR 3810/4885HRH4 3451/4885HSD17B10 3733/4885 |
| US-20170066717-A1 | NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS | NCOR1, NCOR2, NCOA1 | HMGCR 3296/4885HRH4 604/4885HSD17B10 4050/4885 |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | DRD2, CHRM2, NPY2R | HMGCR 3740/4885HRH4 231/4885HSD17B10 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.